[PDF][PDF] Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study
JFR Robertson, A Llombart-Cussac… - Journal of Clinical …, 2009 - researchgate.net
JFR Robertson, A Llombart-Cussac, J Rolski, D Feltl, J Dewar, E Macpherson, J Lindemann…
Journal of Clinical Oncology, 2009•researchgate.netActivity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced
Breast Cancer: Results From the FIRS Page 1 Activity of Fulvestrant 500 mg Versus Anastrozole
1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study John
FR Robertson, Antonio Llombart-Cussac, Janusz Rolski, David Feltl, John Dewar, Euan
Macpherson, Justin Lindemann, and Matthew J. Ellis From the Division of Breast Surgery,
University of Nottingham, Notting- ham; Department of Oncology, Ninewells Hospital and …
Breast Cancer: Results From the FIRS Page 1 Activity of Fulvestrant 500 mg Versus Anastrozole
1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study John
FR Robertson, Antonio Llombart-Cussac, Janusz Rolski, David Feltl, John Dewar, Euan
Macpherson, Justin Lindemann, and Matthew J. Ellis From the Division of Breast Surgery,
University of Nottingham, Notting- ham; Department of Oncology, Ninewells Hospital and …
Purpose
To compare the clinical activity of the pure antiestrogen fulvestrant at 500 mg/mo (double the approved dose) with the aromatase inhibitor anastrozole as first-line endocrine therapy for advanced hormone receptor–positive breast cancer in postmenopausal women.
researchgate.net